2. Search Result
Search Result
Results for "

arterial smooth muscle

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Peptides

1

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-B0464
    Hydralazine hydrochloride
    3 Publications Verification

    		 PGE synthase NO Synthase Reactive Oxygen Species (ROS) DNA Methyltransferase COX Cardiovascular Disease Inflammation/Immunology Cancer
    Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine hydrochloride
  • HY-A0033
    Darifenacin
    Maximum Cited Publications
    7 Publications Verification

    UK-88525

    		 mAChR p38 MAPK Akt Neurological Disease Metabolic Disease Cancer
    Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .
    Darifenacin
  • HY-A0012
    Darifenacin hydrobromide
    Maximum Cited Publications
    7 Publications Verification

    UK-88525 hydrobromide

    		 mAChR p38 MAPK Akt Neurological Disease Metabolic Disease Cancer
    Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .
    Darifenacin hydrobromide
  • HY-16693
    LDN-27219
    1 Publications Verification

    		 Glutaminase Cardiovascular Disease Others
    LDN-27219 is a reversible, slow-binding inhibitor of TGase. LDN-27219 inhibits human TGase with an IC50 value of 0.6 μM. LDN-27219 effectively decreases blood pressure and induces vasodilation, it can be used for the research of cardiovascular disease .
    LDN-27219
  • HY-B1107
    Naftidrofuryl oxalate

    Nafronyl oxalate salt

    		 5-HT Receptor Cardiovascular Disease
    Naftidrofuryl oxalate (Nafronyl oxalate salt) is an orally active 5-HT2 receptor antagonist. Naftidrofuryl oxalate selectively blocks vascular and platelet 5-HT2 receptors, inhibiting Serotonin (HY-B1473A)-induced vasoconstriction, platelet aggregation, and vascular smooth muscle cell proliferation. Naftidrofuryl oxalate can be used for the research of intermittent claudication, peripheral occlusive arterial disease, and critical limb ischaemia .
    Naftidrofuryl oxalate
  • HY-B0464A
    Hydralazine
    3 Publications Verification

    		 DNA Methyltransferase Reactive Oxygen Species (ROS) COX NO Synthase PGE synthase Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Hydralazine is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine
  • HY-P1636
    Hirudin (54-65)

    		Thrombin YAP Calcium Channel Metabolic Disease
    Hirudin (54-65) is a thrombin antagonist and YAP suppressor with anticoagulatory properties.Hirudin (54-65) blocks thrombin's anion binding site, acts on soluble and thrombus-bound thrombin.Hirudin (54-65) suppresses thrombin-induced profibrotic YAP activity, reduces YAP expression, nuclear translocation, and downstream effector signaling in vascular endothelial cells.Hirudin (54-65) ameliorates obstructive cholestasis, attenuates liver fibrosis symptoms, fibrosis-associated angiogenesis, and endothelial-to-mesenchymal transition.Hirudin (54-65) reduces liver inflammation and tissue hypoxia.Hirudin (54-65) promotes extracellular calcium influx through L-type calcium channels in canine coronary artery smooth muscle, mediates contraction.Hirudin (54-65) induces endothelium-independent contraction of canine coronary arterial segments; this response is not affected by indomethacin pretreatment.Hirudin (54-65) can be used for the research of liver obstructive cholestasis, liver fibrosis .
    Hirudin (54-65)
  • HY-11095
    NPS 2390

    		mGluR CaSR PI3K Akt mTOR Autophagy Apoptosis Bcl-2 Family Caspase Cardiovascular Disease Neurological Disease
    NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .
    NPS 2390
  • HY-155106
    SMA4

    		PKG Cardiovascular Disease
    SMA4 is a selective PKG1α activator with basal EC50 value of 29 μM. SMA4 facilitates phosphorylation of the known PKG1 substrate, vasodilator-stimulated phosphoprotein (VASP), and inhibits human pulmonary arterial smooth muscle cells (hPASMC) proliferation. SMA4 can be used for cardiovascular disease research .
    SMA4
  • HY-W153159
    N-Methyltyramine hydrochloride

    		Adrenergic Receptor Inflammation/Immunology
    N-Methyltyramine hydrochloride is an orally active α2-adrenoreceptor antagonist with an IC50 value of 5.53 μM against rat targets. N-Methyltyramine hydrochloride blocks α2-adrenoreceptors, while inhibiting lipolysis, hyperactivity responses and small intestinal peristalsis in mice. N-Methyltyramine hydrochloride promotes gastrin release and pancreatic juice secretion, upregulates appetite, blood pressure, myocardial contraction frequency and contraction intensity, and increases renal blood flow, renal vascular resistance and mean peripheral arterial resistance. N-Methyltyramine hydrochloride relaxes mouse small intestinal smooth muscle and undergoes biotransformation in vivo to produce adrenaline. N-Methyltyramine hydrochloride can be used in studies related to gastrointestinal diseases .
    N-Methyltyramine hydrochloride
  • HY-B0464S1
    Hydralazine-d5 hydrochloride

    		Isotope-Labeled Compounds PGE synthase NO Synthase Reactive Oxygen Species (ROS) DNA Methyltransferase COX Cancer
    Hydralazine-d5 (hydrochloride) is deuterium-labeled Hydralazine (hydrochloride) (HY-B0464). Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine-d5 hydrochloride
  • HY-B0464S
    Hydralazine-d4 hydrochloride

    		Isotope-Labeled Compounds PGE synthase NO Synthase Reactive Oxygen Species (ROS) DNA Methyltransferase COX Cardiovascular Disease
    Hydralazine-d4 hydrochloride is the deuterium labeled Hydralazine hydrochloride. Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine-d4 hydrochloride
  • HY-W507009
    L-Arginyl-L-alanine

    		Endogenous Metabolite Cardiovascular Disease
    L-Arginyl-L-alanine is a dipeptide, is a vascular smooth muscle-derived relaxing factor. L-Arginyl-L-alanine increases the smooth muscle levels of cyclic GMP and nitrite in endothelium-denuded arterial rings .
    L-Arginyl-L-alanine
  • HY-119291
    RA642

    		Phosphodiesterase (PDE) Others
    RA642 is a compound with vasodilatory and hypertensive effects, with the activity of increasing arterial blood pressure, enhancing cerebral blood flow, reducing cerebrovascular resistance and peripheral resistance, and having a papaverine-like relaxant effect on smooth muscle in anesthetized animals.
    RA642
  • HY-172522
    (±)11(12)-DiHET

    		Biochemical Assay Reagents Cardiovascular Disease
    (±)11(12)-DiHET can be converted to a metabolite – 7,8-dihydroxy-hexadecadienoic acid (DHHD). (±)11(12)-DiHET is able to produce relaxation in porcine coronary artery rings. (±)11(12)-DiHET can be studied in research about arterial smooth muscle metabolism .
    (±)11(12)-DiHET
  • HY-W436495
    6,15-Diketo-13,14-dihydro prostaglandin F1α

    6,15-Diketo-13,14-dihydro-PGF1α

    		 Drug Metabolite Metabolic Disease
    6,15-Diketo-13,14-dihydro prostaglandin F1α (6,15-Diketo-13,14-dihydro-PGF1α) is a metabolite of prostacyclin (PGI2). 6,15-Diketo-13,14-dihydro prostaglandin F1α enhances intracellular cAMP and cholesterol metabolism in bovine arterial smooth muscle cells .
    6,15-Diketo-13,14-dihydro prostaglandin F1α
  • HY-171469
    SKP-451

    		Potassium Channel Cardiovascular Disease
    SKP-451 is an ATP-sensitive potassium (K +) channel agonist. SKP-451 activates the ATP-sensitive K + channels, promotes the efflux of K +, causes membrane hyperpolarization, and inhibits the influx of Ca 2+, thereby relaxing the vascular smooth muscle. SKP-451 relaxs the canine coronary artery, rabbit basilar artery, and vertebral artery. SKP-451 also reduces the mean arterial blood pressure of conscious spontaneously hypertensive rats (SHR). SKP-451 is promising for research of cardiovascular diseases .
    SKP-451
  • HY-A0012R
    Darifenacin hydrobromide (Standard)

    UK-88525 hydrobromide (Standard)

    		 Reference Standards mAChR p38 MAPK Akt Neurological Disease Metabolic Disease Cancer
    Darifenacin (hydrobromide) (Standard) is the analytical standard of Darifenacin (hydrobromide). This product is intended for research and analytical applications. Darifenacin (hydrobromide) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin (hydrobromide) binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin (hydrobromide) can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin (hydrobromide) inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .
    Darifenacin hydrobromide (Standard)
  • HY-B0464R
    Hydralazine hydrochloride (Standard)

    		Reference Standards PGE synthase NO Synthase Reactive Oxygen Species (ROS) DNA Methyltransferase COX Cardiovascular Disease Inflammation/Immunology Cancer
    Hydralazine (hydrochloride) (Standard) is the analytical standard of Hydralazine (hydrochloride). This product is intended for research and analytical applications. Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine hydrochloride (Standard)
  • HY-114986
    6-Keto-PGE1
    1 Publications Verification

    6-keto-Prostaglandin E1

    		 β-glucuronidase Cardiovascular Disease
    6-Keto-PGE1 (6-keto-Prostaglandin E1) is a biologically active derivative of PGE1. 6-Keto-PGE1 inhibits adenosine diphosphate-induced platelet aggregation. 6-Keto-PGE1 reduces cardiac afterload, decreases the accumulation of plasma myocardial depressant factor (MDF), lowers arterial blood pressure, dilates vascular beds, inhibits the vasoconstrictive response of vascular smooth muscle, and increases pulmonary compliance. 6-Keto-PGE1 directly stabilizes isolated cat liver lysosomes and significantly reduces the release of β-glucuronidase and cathepsin D. 6-Keto-PGE1 prolongs the survival time of traumatized rats and exerts protective effects through hemodynamic and cytoprotective actions. 6-Keto-PGE1 reduces central airway resistance. 6-Keto-PGE1 can be used in studies related to traumatic shock .
    6-Keto-PGE1
  • HY-182573
    RWJ-58259

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    RWJ-58259 is a selective PAR-1 inhibitor with an IC50 value of 0.15 μM. RWJ-58259 binds selectively to PAR-1, blocks the binding of tethered ligands, interferes with calcium mobilization and PAR-1-related cellular functions, and exhibits no PAR-1 agonist activity or thrombin proteolytic inhibitory activity. RWJ-58259 inhibits thrombin-induced platelet aggregation, calcium signaling and vascular smooth muscle cell proliferation, reduces neointimal thickness and arterial stenosis, and alleviates vascular occlusion and platelet deposition. RWJ-58259 can be used in the research of thrombotic diseases and vascular injury associated with acute coronary intervention .
    RWJ-58259
  • HY-183644
    LNO 9

    		Lysyl Oxidase Cardiovascular Disease
    LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
    LNO 9
  • HY-182616
    CH-123

    		β-glucuronidase Glycosidase Phosphatase Inflammation/Immunology
    CH-123 is an orally active lipid-lowering agent. CH-123 inhibits the elevated activities of β-glucuronidase, β-galactosidase, N-acetyl-β-glucosaminidase and acid phosphatase in aortic smooth muscle cells and hepatocytes. CH-123 reduces serum total lipid and cholesterol levels, as well as intracellular cholesterol content in aortic smooth muscle cells. CH-123 significantly inhibits lysosomal enzyme activity. CH-123 can be used in the research of atherosclerosis .
    CH-123
  • HY-183907
    Cicletanine

    		Calcium Channel Cardiovascular Disease
    Cicletanine is a voltage-dependent Ca 2+ channel inhibitor. Cicletanine inhibits α-adrenoceptor-mediated Ca 2+ release pathway, and shows vasodilatory effects on isolated vascular smooth muscle. Cicletanine directly stimulates lysosomal and cytoplasmic cholesteryl ester hydrolase activity. Cicletanine can be used for the research of hypertension .
    Cicletanine

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: